- Home
- MAIA vs SACH Comparison
MAIA vs SACH Comparison
Compare MAIA & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAIA | SACH |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.9M | 52.0M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MAIA | SACH |
|---|---|---|
| Price | $1.20 | $1.09 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | ★ 454.0K | 181.0K |
| Earning Date | 11-07-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 18.35% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,906,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1.73 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.87 | $0.80 |
| 52 Week High | $2.74 | $1.48 |
Technical Indicators
Market Signals| Indicator | MAIA | SACH |
|---|---|---|
| Relative Strength Index (RSI) | 53.94 | 57.96 |
| Support Level | $1.07 | $1.00 |
| Resistance Level | $1.25 | $1.08 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 55.93 | 72.22 |
Price Performance
Historical ComparisonAbout MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.